Transcript
Indiana University Narrator (0:00)
Indiana University strengthens tomorrow's workforce with practical real world experience. IU grads make a difference in your community, serving as teachers, nurses and engineers who rise to tomorrow's challenges and meet them. Learn more at iu.edu impact,
Bloomberg Audio Announcer (0:20)
Bloomberg Audio
Linda Yaccarino (0:21)
Studios Podcasts Radio News let's take a
Interviewer (0:25)
little bit of a detour right now because two prominent names in sports and business have joined for is to tackle one of the fastest growing health costs. GLP wants the former CEO of X. Her name is Linda Yaccarino. She has teamed up with NFL legend Tom Brady Brady partner to build in that. I know, right? We're sitting right here. But let me just tell you what EMED is. It's a platform dedicated to helping employers manage costs associated with weight loss drugs. Linda serves as CEO. Tom is a co owner and Chief Wellness officer and I am just delighted that they're both sitting to my right. Thank you guys for joining us.
Linda Yaccarino (1:00)
Thank you for having us. We really appreciate it.
Interviewer (1:03)
So let's talk a little bit about how this all came together and I'll start with both of you individually and Linda, I'll start with you because you took the helm of EMED after spending two years as the CEO of X formerly known as Twitter. And I would just love to hear about, you know, how that happened. What sort of translates from social media into, you know, running a telehealth company.
Linda Yaccarino (1:27)
I thank you so much. It's a great question. And when I look back on my career, which will, I think logically explain how I landed at emed, you could probably mark it by one or two words and it would be transformation led by technology, transformation and innovation. Right. So throughout my career, whether I was at NBCU for so long, one of the outputs of that was launching Peacock to then go to Twitter and then X in creating the global town square. It made sense. Once I decided to leave X, what should I do next? And about six months prior to leaving X, I became chair of the board of EMED's director consumer business in England, the number one female focused GLP1 business. And why it all came together is because what I learned and was so impacted by the profound nature of the power of these GLP1 medications. And I certainly knew that access needed to happen for people, particularly in the United States. 60% of people get their benefits from their employer and only 1 in 5 employers cover GLP1s right now. So once I was really thinking and considering what to do, tackling transformation in health care to give people access to these life changing medications was a was an easy answer.
